Literature DB >> 3528559

[Burkitt's lymphoma of the bilateral breasts presenting during lactation].

T Nomizu, A Tsuchiya, T Nemoto, H Sato, I Watanabe, R Abe, Y Nozawa, K Tominaga, H Wakasa, T Hoshino.   

Abstract

A 34-year-old postpartum woman with Burkitt's lymphoma is reported. Lymphoma involved the bilateral breasts chiefly, as well as the brain, ileocecal region and supraclavicular lymph nodes. Fourteen days after bilateral mastectomy, the patient suddenly went into a coma due to rapid progress of brain involvement. However, the coma improved the day after VEPA chemotherapy and radiation were undertaken, and the tumor-involved brain decreased significantly in size following chemoradiotherapy. Chemoradiotherapy produced the almost complete disappearance of the remaining tumor. The patient is now being treated by a maintenance dose of Endoxan and is doing well. Burkitt's lymphoma of the breast in the present case had the clinical characteristics of bilateral involvement with rapid growth arising during lactation and pregnancy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3528559

Source DB:  PubMed          Journal:  Gan No Rinsho        ISSN: 0021-4949


  2 in total

Review 1.  Primary bilateral Burkitt lymphoma of the lactating breast: a case report and review of the literature.

Authors:  Shahrzad Negahban; Nasrollah Ahmadi; Ahmad Oryan; Habib N Khojasteh; Azita Aledavood; Hossein Soleimanpour; Mohammad Mohammadianpanah; Ilske Oschlies; Stefan Gesk; Reiner Siebert; Khosrow Daneshbod; Yahya Daneshbod
Journal:  Mol Diagn Ther       Date:  2010-08-01       Impact factor: 4.074

2.  An autopsy case of peripheral T cell lymphoma occurring in a postpartum woman: a unique case suggesting changes in the immunocharacteristics of lymphoma cells before and after delivery.

Authors:  Kenichi Mizutani; Sohsuke Yamada; Xin Guo; Chizuru Futatsuya; Motona Kumagai; Akihiro Shioya; Akane Aikawa; Satoko Nakada; Nozomu Kurose; Hiroshi Minato; Takayuki Nojima
Journal:  Diagn Pathol       Date:  2018-05-22       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.